NCT01717482

Metformin as a Chemoprevention Agent in Non-small Cell Lung Cancer

A Pilot Study of Metformin as a Chemoprevention Agent in Non-small Cell Lung Cancer

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 6 (actual)
• Sponsor: Mayo Clinic · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to learn whether it is better to receive the drug Metformin with standard of care for lung cancer or just standard of care.

Detailed description

Participants will need to be scheduled to undergo a surgical resection of their lung cancer at the Mayo Clinic in Rochester, Minnesota. They will be asked to provide a blood sample prior to their surgery. Samples of tumor tissue and normal lung tissue will be taken from the samples removed during your lung surgery. The tissue will be used to evaluate DNA. A skin biopsy at the edge of the incision that has already been made will be done during your surgery. We will take the skin and grow skin fibroblasts. Then we will reprogram the skin fibroblasts into induced pluripotent cells. You will be "randomized" into one of the study groups to either take Metformin for 6 months with your standard of care follow up or to receive standard of care follow up.

Conditions

• Lung Neoplasms
• Carcinoma, Non-Small-Cell Lung

Interventions

Type	Name	Description
DRUG	Metformin
OTHER	Placebo Comparator	Standard of Care Observation

Timeline

• Start date: 2012-10-01
• Primary completion: 2019-05-22
• Completion: 2019-05-22
• First posted: 2012-10-30
• Last updated: 2020-03-10
• Results posted: 2019-06-19

Locations

1 site across 1 country: United States